Dallas, TX -- (SBWIRE) -- 06/10/2015 -- The report "Postherpetic Neuralgia – Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Postherpetic Neuralgia. Postherpetic neuralgia is a complication of shingles, which is caused by the herpes zoster virus. Currently, there's no cure for postherpetic neuralgia, but there are treatment options to ease symptoms. Signs and symptoms may include Pain, Sensitivity to light touch, Itching and numbness, Weakness or paralysis.

Complete report on Postherpetic Neuralgia with 38 market data tables and 14 figures, spread across 107 pages is available at http://www.rnrmarketresearch.com/postherpetic-neuralgia-pipeline-review-h1-2015-market-report.html.

Companies discussed in this Postherpetic Neuralgia – Pipeline Review, H1 2015 report include Aestus Therapeutics, Inc., Allergan, Inc., Arcion Therapeutics, Inc., Astellas Pharma Inc., Daewoong Pharmaceutical Co., Ltd., Daiichi Sankyo Company, Limited, Immune Pharmaceuticals, Ltd., Intellipharmaceutics International Inc., Merck & Co., Inc., NeurAxon, Inc., Nuvo Research Inc., Pfizer Inc., Phosphagenics Limited, Purdue Pharma L.P., Relmada Therapeutics, Inc., Scilex Pharmaceuticals, Inc., Spinifex Pharmaceuticals Pty Limited, Teva Pharmaceutical Industries Limited, Winston Pharmaceuticals, Inc.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Drug Profiles mentioned in this report are (amitriptyline + ketamine hydrochloride), (naltrexone hydrochloride+ clonidine hydrochloride), ASP-8477, Atx08-001, bupivacaine hydrochloride, C-746, CNV-2197944, DWP-05195, EMA-401, Flexicaine, FV-100, ketoprofen, lidocaine, lidocaine hydrochloride, mepivacaine hydrochloride, mirogabalin, MK-8291, NXN-462, oxycodone ER, pregabalin CR, pregabalin ER, senrebotase, TV-45070, V-116517, zucapsaicin.

Order a purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=390972 . (This is a premium report priced at US$2000 for a single user License.)

Featured News & Press Releases Cover by this report includes:
- Apr 02, 2015: Teva and Xenon Announce Enrollment of First Patient in a Phase 2b Study Evaluating TV-45070 for Postherpetic Neuralgia
- Feb 20, 2015: ContraVir Pharmaceuticals Provides Clinical Update on FV-100
- Feb 19, 2015: Xenon Pharmaceuticals Partner Teva to Initiate Phase 2b Clinical Trial of TV-45070 in Post-Herpetic Neuralgia
- Feb 04, 2015: Daiichi Sankyo Announces First Patients in Large-scale, Multi-national Phase 3 Clinical Programs for Mirogabalin
- Jan 07, 2015: ContraVir Pharmaceuticals Granted FDA Meeting to Discuss Proposal for Phase 3 Trial of FV-100
- Dec 18, 2014: Pfizer Reports Top-Line Results From a Phase 3 Study Evaluating Pregabalin Controlled-Release Formulation as a Treatment for Patients With Postherpetic Neuralgia
- Aug 11, 2014: Scilex Pharmaceuticals Completes Trial Enrollment for Ztlido
- Jul 14, 2014: SCILEX Pharmaceuticals Commences Dermal Safety Studies of Ztlido
- May 19, 2014: Scilex Pharmaceuticals Initiates Pivotal Pharmacokinetic Study for Ztilido
- Mar 24, 2014: Scilex Pharmaceuticals Announces Filing of Investigational New Drug Application for Ztilido

Inquire for Disocunt @ http://www.rnrmarketresearch.com/contacts/discount?rname=390972. (This is a premium report priced at US$2000 for a single user License.)

List of Tables
Number of Products under Development for Postherpetic Neuralgia, H1 2015 10
Number of Products under Development for Postherpetic Neuralgia - Comparative Analysis, H1 2015 11
Number of Products under Development by Companies, H1 2015 13
Comparative Analysis by Late Stage Development, H1 2015 14
Comparative Analysis by Clinical Stage Development, H1 2015 15
Comparative Analysis by Early Stage Development, H1 2015 16
Comparative Analysis by Unknown Stage Development, H1 2015 17
Products under Development by Companies, H1 2015 18
Products under Development by Companies, H1 2015 (Contd..1) 19
Postherpetic Neuralgia - Pipeline by Aestus Therapeutics, Inc., H1 2015 20
Postherpetic Neuralgia - Pipeline by Allergan, Inc., H1 2015 21
Postherpetic Neuralgia - Pipeline by Arcion Therapeutics, Inc., H1 2015 22
Postherpetic Neuralgia - Pipeline by Astellas Pharma Inc., H1 2015 23
Postherpetic Neuralgia - Pipeline by Daewoong Pharmaceutical Co., Ltd., H1 2015 24
Postherpetic Neuralgia - Pipeline by Daiichi Sankyo Company, Limited, H1 2015 25
Postherpetic Neuralgia - Pipeline by Immune Pharmaceuticals, Ltd., H1 2015 26
Postherpetic Neuralgia - Pipeline by Intellipharmaceutics International Inc., H1 2015 27
Postherpetic Neuralgia - Pipeline by Merck & Co., Inc., H1 2015 28
Postherpetic Neuralgia - Pipeline by NeurAxon, Inc., H1 2015 29
Postherpetic Neuralgia - Pipeline by Nuvo Research Inc., H1 2015 30
Postherpetic Neuralgia - Pipeline by Pfizer Inc., H1 2015 31
Postherpetic Neuralgia - Pipeline by Phosphagenics Limited, H1 2015 32
Postherpetic Neuralgia - Pipeline by Purdue Pharma L.P., H1 2015 33
Postherpetic Neuralgia - Pipeline by Relmada Therapeutics, Inc., H1 2015 34
Postherpetic Neuralgia - Pipeline by Scilex Pharmaceuticals, Inc., H1 2015 35
Postherpetic Neuralgia - Pipeline by Spinifex Pharmaceuticals Pty Limited, H1 2015 36
Postherpetic Neuralgia - Pipeline by Teva Pharmaceutical Industries Limited, H1 2015 37
Postherpetic Neuralgia - Pipeline by Winston Pharmaceuticals, Inc., H1 2015 38
Assessment by Monotherapy Products, H1 2015 39
Assessment by Combination Products, H1 2015 40
Number of Products by Stage and Target, H1 2015 42
Number of Products by Stage and Mechanism of Action, H1 2015 44
Number of Products by Stage and Route of Administration, H1 2015 46
Number of Products by Stage and Molecule Type, H1 2015 48
Postherpetic Neuralgia Therapeutics - Recent Pipeline Updates, H1 2015 83
Postherpetic Neuralgia - Dormant Projects, H1 2015 97
Postherpetic Neuralgia - Dormant Projects (Contd..1), H1 2015 98
Postherpetic Neuralgia - Discontinued Products, H1 2015 99

List of Figures
Number of Products under Development for Postherpetic Neuralgia, H1 2015 10
Number of Products under Development for Postherpetic Neuralgia - Comparative Analysis, H1 2015 11
Number of Products under Development by Companies, H1 2015 12
Comparative Analysis by Clinical Stage Development, H1 2015 15
Assessment by Monotherapy Products, H1 2015 39
Assessment by Combination Products, H1 2015 40
Number of Products by Top 10 Targets, H1 2015 41
Number of Products by Stage and Top 10 Targets, H1 2015 41
Number of Products by Top 10 Mechanism of Actions, H1 2015 43
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 43
Number of Products by Top 10 Routes of Administration, H1 2015 45
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 46
Number of Products by Top 10 Molecule Types, H1 2015 47
Number of Products by Stage and Top 10 Molecule Types, H1 2015 48

Explore more reports on Dermatology therapeutics at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/dermatology-therapeutics.

About RnRMarketResearch.com
RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.